A Phase 1 Study of CSL362 (Anti-IL3Ralpha/ Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse

Trial Profile

A Phase 1 Study of CSL362 (Anti-IL3Ralpha/ Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Talacotuzumab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors CSL
  • Most Recent Events

    • 12 Mar 2016 Population pharmacokinetic/pharmacodynamics analysis (n=27) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 08 Dec 2015 Results of exploratory endpoint (minimal residual disease) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top